Citations

Clear

3942 citation(s) found for "To, Van".

Abstract 2968: Postmortem Genetic Testing of the GPD1-L-Encoded Glycerol-3-Phosphate Dehydrogenase 1-Like Protein in Sudden Infant Death Syndrome
Norstrand, David W. Van, Valdivia, Carmen R. , Tester, David J. , Ueda, Kazuo , Makielski, Jonathan C., Ackerman, Michael J. , London, Barry

Mayo Clinic

Circulation | July 3, 2021 | Volume: 116 | Issue: suppl_16 | Pages: No page available

10.1161/circ.116.suppl_16.ii_663-a Get It

Introduction: Approximately 10 – 15% of sudden infant death syndrome (SIDS) may be caused by cardiac channelopathies including Brugada syndrome (BrS). Type 1 BrS (BrS1), due to mutations in the SCN5A-encoded sodium channel, accounts for approximately 20% of BrS. Recently, a novel mutation in glycerol-3-phosphate dehydrogenase 1-like (GPD1-L) disrupted trafficking of SCN5A in a multi-generational family with BrS. We hypothesized that mutations in GPD1-L may be responsible for some cases of SIDS. Methods: Using DHPLC and direct DNA sequencing, we performed comprehensive open reading frame/splice site mutational analysis of GPD1-L on genomic DNA extracted from necropsy tissue of 228 anonymous cases of SIDS (86 females, 142 males, average age = 3 + 2 months, range 6 hours to 12 months). Results: Three putative, SIDS-associated GPD1-L missense mutations, E83K, I124V, and R273C, were discovered in a three-month-old white male, a five-week-old white female, and a one-month-old white male, respectively. All mutations occurred in highly conserved residues and were absent in 600 reference alleles. Compared to wild type GPD1-L, GPD1-L mutations co-expressed with SCN5A in heterologous HEK cells produced a 60% reduction in peak sodium current density (p<0.004). Adenovirus-mediated gene transfer of the E83K-GPD1-L mutation into neonatal mouse myocytes markedly attenuated the sodium current as well (p<0.01). These decreases in current density are consistent with sodium channel loss-of-function diseases like BrS. Conclusion: This study is the first to report mutations in GPD1-L as a pathogenic cause for a small subset (~1%) of SIDS via a secondary loss-of-function mechanism whereby perturbations in GPD1-L precipitate a marked decrease in the peak sodium current and a potentially lethal, BrS-like pro-arrhythmic substrate.
Abstract 3090: Missense Mutations in SNTA1-Encoded Syntrophin Alpha and Sudden Infant Death Syndrome
Norstrand, David W. Van, Tester, David J. , Cheng, Jianding , Valdivia, Carmen R. , Makielski, Jonathan C., Ackerman, Michael J. , Medeiros‐Domingo, Argelia

Mayo Clinic

Circulation | July 3, 2021 | Volume: 118 | Issue: suppl_18 | Pages: No page available

10.1161/circ.118.suppl_18.s_812-c Get It

An estimated 10–15% of sudden infant death syndrome (SIDS) may be channelopathic with approximately half of the SIDS-associated channel mutations involving the sodium channel (NaV1.5) macromolecular complex. Recently, SNTA1, which encodes the sodium channel interacting protein (ChIP), syntrophin alpha, was discovered to be a novel long QT syndrome (LQTS) susceptibility gene (LQT12) with mutations causing increased late sodium current secondary to increased s-nitrosylation of the sodium channel’s alpha subunit. Therefore, SNTA1 is a plausible candidate gene for SIDS. In this IRB-approved study, mutational analysis of SNTA1’s eight translated exons was performed using PCR, DHPLC, and direct DNA sequencing of DNA derived from 286 SIDS cases (112 females, 197 white, average age 2.9 ± 1.9 months, range 3 days -12 months). The anonymized study design precluded a determination of mutation status as familial or sporadic. Overall, 8/286 cases of SIDS harbored missense mutations in SNTA1 that were absent in 800 reference alleles. Six distinct, rare SNTA1 missense mutations were detected in 7/112 (6.25%) female infants but only 1/174 (0.6%) male infants (p < 0.01). Comprehensive open reading frame analysis of all 800 reference alleles also revealed rare genetic variants in 1% of the control subjects. A common pair of non-synonymous single nucleotide polymorphisms (P74L/A257G), with a heterozygous frequency of 1%, was identified similarly in both cases and controls. This study provides the first molecular evidence implicating mutations in SNTA1 as a novel pathogenic substrate for channelopathic SIDS. However, given the ~1% background rate of rare variants in controls, mechanistic studies of each putative SIDS-associated SNTA1 mutation will be necessary to confirm that the mutant ChIP yields a functionally perturbed NaV1.5 macromolecular complex akin to the investigations that established SNTA1 as a novel LQTS-susceptibility gene.
Abstract 16602: Pulmonary Vascular Response to Metaboreflex Stimulation During Submaximal Exercise in Heart Failure
Snyder, Eric M., Johnson, Bruce D., Olson, Thomas P. , Iterson, Erik H. Van

Mayo Clinic

Circulation | July 3, 2021 | Volume: 130 | Issue: suppl_2 | Pages: No page available

10.1161/circ.130.suppl_2.16602 Get It

Introduction: Neural feedback from skeletal muscle during exercise contributes to changes in pulmonary pressures in healthy individuals. Heart failure patients (HF) often develop pulmonary hypertension; however, the relationship between muscle afferent feedback and the pulmonary vasculature in HF remains unclear. Hypothesis: We examined the influence of metaboreceptor stimulation on pulmonary vascular capacitance using a validated non-invasive gas exchange equivalent (GX CAP ) in HF. Methods: Eleven HF patients (age 51±5 yrs; EF, 32±3%; NYHA class, 1.6±0.2) and 11 controls (CTL; age 43±3 yrs) completed 3 cycling session (4-min at 60% of peak oxygen consumption, VO 2 ). Session one: baseline control trial. Sessions 2 and 3: bilateral upper-thigh tourniquets inflated suprasystolic for 2 min at end-exercise (regional circulatory occlusion, RCO) with or without addition of inspired CO 2 to maintain end-exercise end-tidal CO 2 (P ET CO 2 ) (RCO+CO 2 ) (randomized). Rest, exercise, and recovery heart rate (HR), P ET CO 2 , and VO 2 were measured. O 2 pulse (VO 2 /HR) and GX CAP (O 2 pulseхP ET CO 2 ) were calculated. Results: During all conditions at end-exercise, HF demonstrated significantly lower GX CAP compared to CTL (p<0.01). Percent change in GX CAP from end-exercise to 2 min post-exercise was attenuated in HF compared to CTL (41±5% vs 64±1%, respectively, p<0.01) during the baseline trial. During RCO, HF had a 55±6% reduction in GX CAP from end-exercise compared to 77±2% in CTL (p<0.01). During RCO+CO 2 , HF had a 49±4% reduction in GX CAP from end-exercise compared to 69±2% in CTL (p<0.01). GX CAP was similar between sessions within HF. The CTL group demonstrated an attenuated return of GX CAP during RCO compared to both baseline and RCO+CO 2 (p<0.01) with no difference between baseline and RCO+CO 2 . Conclusion: These data suggest the exercise mediated rise and post-exercise recovery of pulmonary vascular capacitance are attenuated in HF during constant-load submaximal exercise compared to CTL. Additionally, our data confirm previous reports that locomotor muscle afferent feedback influences pulmonary vascular capacitance in CTL; however, this model of locomotor muscle metaboreflex stimulation appears to a differential response in HF compared to CTL.
MCIR1: A patient‐derived mantle cell lymphoma line for discovering new treatments for ibrutinib resistance
Wu, Xiaosheng , Nowakowski, Kevin E., Abeykoon, Jithma P. , Stenson, Mary, Timm, Michael, Hanson, Curtis A. , Dyke, Daniel L. Van , Dasari, Surendra , Stenson, Mary J, Timm, Michael M, Van Dyke, Daniel L, Wu, Xiaosheng , Manske, Michelle K. , Witzig, Thomas E.

Mayo Clinic

European Journal of Haematology | July 2, 2021 | Volume: 107 | Issue: 4 | Pages: 458-465

10.1111/ejh.13682 | PMID 34214199 Get It

AbstractBackgroundDespite the unprecedented success of ibrutinib in lymphoma therapy, the development of ibrutinib resistance due to acquired BTK or PLCγ2 mutations has become a new clinical problem. However, not all resistance is mediated by these mutations and these mechanisms are poorly understood due to a lack of study tools that truly recapitulate this clinical scenario.MethodsWe established a novel patient‐derived ibrutinib‐resistant mantle cell lymphoma (MCL) line named MCIR1. Using immunological, molecular, and cytogenetic approaches, we comprehensively characterized MCIR1 and further demonstrated its utility in the study of resistance mechanisms and treatments to overcome this resistance.ResultsWe show that MCIR1 is a bona fide ibrutinib‐resistant MCL cell line with normal BTK‐/PLCγ2 but ibrutinib‐resistant ERK1/2 and AKT1 signaling. RNA‐Seq analysis revealed a robust non‐canonical NF‐kB signaling that drives the ibrutinib resistance. We also demonstrate the potential utility of a MCIR1‐based cell and mouse model for the discovery of new treatments to overcome BTK inhibitor resistance.ConclusionsWe have established the first patient‐derived ibrutinib‐resistant MCL cell line MCIR1 that lacks BTK or PLCγ2 mutations but exhibits a hyperactive non‐canonical NF‐kB pathway. We further demonstrate its utility in the discovery and validation of new drugs to overcome this resistance.
Genome-wide Interaction Analysis of Menopausal Hormone Therapy Use and Breast Cancer Risk among 62,370 Women
Kapoor, Pooja, Auer, Paul, Dennis, Joe, Wang, Qin , Bolla, Manjeet K. , Aronson, Kristan J. , Lee, Derrick , Cordina‐Duverger, Emilie, Mulot, Claire , Teras, Lauren R., Patel, Alpa V. , Hoppe, Reiner , Lo, Wing‐Yee, Brüning, Thomas , Hamann, Ute, Couch, Fergus, Ruddy, Kathryn J. , MacInnis, Robert J. , Wilkens, Lynne, Haiman, Christopher A. , Krüger, Ute , Wagner, Philippe , Vachon, Celine M. , Eliassen, Heather, Andrulis, Irene L. , Evans, D. Gareth , Ziogas, Argyrios, Orr, Nick , Linet, Martha S. , Prentice, Ross L. , Easton, Douglas F. , Chang‐Claude, Jenny , Lindström, Sara , Evans, D Gareth , Maclnnis, Robert , Orr, Nick , Wang, Xiaoliang , Kapoor, Pooja, Dunning, Alison M. , Lush, Michael J. , Michailidou, Kyriaki , Murphy, Rachel A. , Brooks‐Wilson, Angela , Guénel, Pascal , Truong, Thérèse , Teras, Lauren R. , Dossus, Laure , Kaaks, Rudolf , Czene, Kamila , Gabrielson, Marike , Hall, Per N , Eriksson, Mikael , Jung, Audrey , Becher, Heiko , Couch, Fergus J. , Larson, Nicole, Olson, Janet E. , Giles, Graham G. , Southey, Melissa C. , Marchand, Loı̈c Le , Wilkens, Lynne R. , Olsson, Håkan , Augustinsson, Annelie , Scott, Christopher, Winham, Stacey J. , Vachon, Celine M. , Perou, Charles M. , Olshan, Andrew F. , Troester, Melissa A. , Hunter, David, Eliassen, A. Heather , Tamimi, Rulla M. , Brantley, Kristen D. , Figueroa, Jonine D. , Chanock, Stephen Jacob , Ahearn, Thomas U. , García‐Closas, Montserrat , Newman, William G. , Veen, Elke M. van , Howell, Anthony , Wolk, Alicja , Håkansson, Niclas , Anton‐Culver, Hoda , Jones, Michael E. , Schoemaker, Minouk J. , Swerdlow, Anthony J. , Kitahara, Cari M. , Milne, Roger L. , Kraft, Peter

Mayo Clinic

No container title available | July 2, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-532921/v2 Get It

Abstract Background: Use of menopausal hormone therapy (MHT) is associated with increased risk for breast cancer. However, the relevant mechanisms and its interaction with genetic variants are not fully understood. Methods: We conducted a genome-wide interaction analysis between MHT use and genetic variants for breast cancer risk in 27,585 cases and 34,785 controls from 26 observational studies. All women were post-menopausal and of European ancestry. Multivariable logistic regression models were used to test for multiplicative interactions between genetic variants and current MHT use. We considered interaction p-values<5x10-8 as genome-wide significant, and p-values<1x10-5 as suggestive. Linkage disequilibrium (LD)-based clumping was performed to identify independent candidate variants.Results: None of the 9.7 million genetic variants tested for interactions with MHT use reached genome-wide significance. Only 213 variants, representing 18 independent loci, had p-values<1x105. The strongest evidence was found for rs4674019 (p-value=2.27x10-7), which showed genome-wide significant interaction (p-value=3.8x10-8) with current MHT use when analysis was restricted to population-based studies only. Limiting the analyses to combined estrogen-progesterone MHT use only or to estrogen receptor (ER) positive cases did not identify any genome-wide significant evidence of interactions. Conclusions: In this large genome-wide SNP-MHT interaction study of breast cancer, we found no strong support for common genetic variants modifying the effect of MHT on breast cancer risk. These results suggest that common genetic variation has limited impact on the observed MHT–breast cancer risk association.
Abstract CT219: Master protocol to assess the safety and recommended Phase 2 dose of next generation NY-ESO-1-specific TCR T-cells in HLA-A*02 patients with synovial sarcoma and non-small cell lung cancer
Altan, Mehmet , Ladle, Brian H. , Noujaim, Jonathan , Yachnin, Jeffrey , Huang, Chao , Hasan, Aisha , Faitg, Thomas, Butler, Emily, Shalabi, Aiman, Attia, Steven , Araujo, Dejka M. , Schoenfeld, Adam Jacob , Owonikoko, Taofeek Kunle , D'Angelo, Sandra P , He, Kai , Liebner, David A. , Sacher, Adrian Gerold , Haanen, John B A G , Tine, Brian A. Van , Butler, Emily

Mayo Clinic

Cancer Research | July 1, 2021 | Volume: 81 | Issue: 13_Supplement | Pages: CT219-CT219

10.1158/1538-7445.am2021-ct219 Get It

Abstract Background: Letetresgene autoleucel (lete-cel; GSK3377794) is an autologous T-cell therapy expressing a genetically modified T-cell receptor (TCR) to improve recognition of cancer cells expressing NY-ESO-1 and/or LAGE-1a. Next generation NY-ESO-1 TCR T-cell therapies, including GSK3901961 and GSK3845097, incorporate further genetic modifications to enhance anticancer activity. GSK3901961 co-expresses the CD8α chain to stabilize TCR-human leukocyte A (HLA) class I interactions on CD4+ T cells, enhancing T-cell persistence and increasing helper functions such as Type 1 T-helper anti-tumor responses. GSK3845097 co-expresses a dominant negative transforming growth factor-β (TGF-β) type II receptor to reduce TGF-β pathway activation and maintain T-cell proliferation, cytokine production, and cytotoxicity in the tumor microenvironment. A first-time-in-human master protocol (NCT04526509) will evaluate the safety, tolerability, and recommended Phase 2 dose (RP2D) of these two therapies and possible subsequent ones. Substudy 1 will assess GSK3901961 in patients with advanced non-small cell lung cancer (NSCLC) or synovial sarcoma (SS). Substudy 2 will assess GSK3845097 in patients with advanced SS. Methods: Each substudy includes a dose confirmation stage to assess RP2D and a dose expansion stage. Table 1 lists eligibility criteria. Primary endpoints are safety (adverse events) and tolerability (dose-limiting toxicities). Secondary endpoints include investigator-assessed overall response rate, duration of response, and maximum expansion/persistence and phenotype of infiltrating transduced T cells. Exploratory endpoints include laboratory parameters, overall survival, and anti-GSK3901961 and anti-GSK3845097 titers for the respective substudies. The substudies are open and recruiting. Funding: GSK (209012; NCT04526509) Initial screening criteriaInclusion criteriaExclusion criteriaSubstudies 1 and 2 (SS and NSCLC)≥18 years of agePrior malignancy that is not in complete remission or clinically significant systemic illnessMeasurable disease per RECIST v1.1 criteriaPrevious treatment with genetically modified NY-ESO-1-specific T cells, NY-ESO-1 vaccine, or NY-ESO-1 targeting antibodyExpression of HLA-A*02:01, A*02:05, or A*02:06Prior gene therapy using an integrating vectorExpression of NY-ESO-1/LAGE-1a in tumor archival or fresh biopsyPrevious allogeneic hematopoietic stem cell transplant within the last 5 years or solid organ transplantSubstudies 1 and 2 (SS only)Histologically confirmed advanced (metastatic or unresectable) SS diagnosisCentral nervous system metastasesPresence of t(X;18) translocation(Allowed for NSCLC participants on a case-by-case basis)Received, completed, or intolerant to treatment with anthracycline or anthracycline with ifosfamide for advanced (metastatic or unresectable) disease and has progressedSubstudy 1 (NSCLC only)Histologically or cytologically confirmed Stage IV NSCLCReceived or failed ≥3 lines of systemic therapyReceiving or previously received ≥1 prior line(s) of standard of care treatment including programmed death receptor-1/programmed death ligand-1 checkpoint blockade therapy, and received or be intolerant to doublet taxane and platinum chemotherapyPresence of actionable genetic aberration (activation epithelial growth factor receptor, anaplastic lymphoma kinase/c-ros oncogene 1) per NCCN guidelines Citation Format: Adam J. Schoenfeld, Mehmet Altan, Taofeek K. Owonikoko, Sandra D'Angelo, Brian H. Ladle, Jonathan Noujaim, Kai He, David Liebner, Adrian G. Sacher, John B.A.G. Haanen, Jeffrey Yachnin, Chao Huang, Brian A. Van Tine, Aisha Hasan, Thomas Faitg, Emily Butler, Aiman Shalabi, Steven Attia, Dejka M. Araujo. Master protocol to assess the safety and recommended Phase 2 dose of next generation NY-ESO-1-specific TCR T-cells in HLA-A*02 patients with synovial sarcoma and non-small cell lung cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr CT219.
Abstract CT130: Phase 1 study of the novel immunotoxin MT-5111 in patients with HER-2+tumors
Mita, Monica , Valdes, Frances, Ahn, Daniel H. , Starr, Jason S. , Burnett, Christine, Pelham, Joshua, Anand, Banmeet, Strack, Thomas , Sandri, Andrés Machado, Wainberg, Zev A. , Barve, Minal , Hamilton, Erika , Brenner, Andrew Jacob , Hubbard, Joleen M. , Williams, Eric T. , Tine, Brian A. Van

Mayo Clinic

Cancer Research | July 1, 2021 | Volume: 81 | Issue: 13_Supplement | Pages: CT130-CT130

10.1158/1538-7445.am2021-ct130 Get It

Abstract Background: Engineered toxin bodies (ETBs), composed of an engineered Shiga-like Toxin A subunit genetically fused to an antibody-binding domain, can force receptor internalization, induce potent cell-kill via enzymatic and permanent inactivation of ribosomes, and may not be subject to resistance mechanisms of other targeted agents. MT-5111, a de-immunized 55 kD ETB targeting HER2 in solid tumors, also binds to an epitope distinct from trastuzumab and pertuzumab, which may permit combination strategies with other HER2 targeting agents. Methods: The primary objective is to determine maximum tolerated dose (MTD) of MT-5111 monotherapy in adult patients (pts) with advanced HER2+ solid tumors. Secondary objectives are PK, efficacy, and immunogenicity. Using a modified 3+3 design, the dose-escalation part of the study includes the following 7 cohorts: 0.5, 1, 2, 3, 4.5, 6.75, and 10 µg/kg. Three dose-expansion cohorts will follow for HER2+ breast cancer, gastro-esophageal cancer, and any other HER2+ tumors. All pts will receive MT-5111 weekly as a 30-min IV infusion in each 21-d treatment (tx) cycle (C) until disease progression (PD), unacceptable toxicity, death, or withdrawn consent (NCT04029922). Results: As of the data cut in December 2020, 16 pts were treated; cancer types included breast (n=6), gastric (n=1), colon (n=1), gallbladder (n=5), and other solid tumors (n=3). Mean age was 64 years (range, 34-78); 37.5% were male. Pts received a median of 4 prior lines of systemic therapies (range, 1-8). No G4 or G5 TEAEs occurred. Six pts had 11 G3 TEAEs; the most common were increased AST and dyspnea (both n=2). Three pts had tx-emergent serious adverse events (abdominal distension [n=1]; dyspnea [n=2]). Tx-related TEAEs occurred in 8 (50%) pts; the most common was fatigue (n=5, 31.3%) and all were ≤ grade 2 in nature, except for one grade 3 event of dyspnea. No cardiac TEAEs, clinically significant changes in cardiac biomarkers (troponin, electrocardiogram, left ventricular ejection fraction), or cases of capillary leak syndrome were observed. Fifteen pts discontinued with PD; 1 pt in cohort 5 (4.5 µg/kg) is on tx with stable disease. To date, no DLTs have been observed and the MTD has not been reached. One pt in cohort 2 (1 µg/kg) had resolution of all hepatic lesions (sub-centimeter lesions pre-tx) at the end of C8; however, the pt came off study due to clinical progression at the end of C10. PK data for the first 5 cohorts matched simulations based on non-human primate studies. Conclusions: MT-5111 was well tolerated with no clinically significant cardiotoxicity. Continued dose escalations are ongoing. Citation Format: Zev A. Wainberg, Monica M. Mita, Minal A. Barve, Erika P. Hamilton, Andrew J. Brenner, Frances Valdes, Daniel Ahn, Joleen Hubbard, Jason Starr, Christine Burnett, Joshua Pelham, Eric T. Williams, Banmeet S. Anand, Thomas Strack, Andrés Machado Sandri, Brian A. Van Tine. Phase 1 study of the novel immunotoxin MT-5111 in patients with HER-2+tumors [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr CT130.
Post‐discharge arrhythmic risk stratification of patients with acute myocarditis and life‐threatening ventricular tachyarrhythmias
Gentile, Piero , Merlo, Marco , Peretto, Giovanni , Bella, Paolo Della , Aquaro, Giovanni Donato , Potena, Luciano , Campodonico, Jeness , Foà, Alberto , Hazebroek, Mark R. , Čerček, Andreja Černe , Shrivastava, Sanskriti , Heyning, Caroline M. Van De , Craenenbroeck, Emeline M. Van , Sugimura, Koichiro , Cannatà, Antonio , Porcari, Aldostefano , Colopi, Marzia , Perkan, Andrea, Garascia, Andrea , Pereira, Naveen L. , Heymans, Stéphane , Camici, Paolo G. , Frigerio, Maria , Potena, Luciano , Van De Heyning, Caroline M , Heymans, Stephane , Porcari, Aldostefano , Foà, Alberto , Gentile, Piero , Cannatà, Antonio , Ammirati, Enrico , Sala, Simone , Imazio, Massimo , Raafs, Anne G. , Brambatti, Michela , Nucifora, Gaetano , Huang, Florent , Schmidt, Matthieu , Muser, Daniele , Aoki, Tatsuo , Shimokawa, Hiroaki , Artico, Jessica , Bussani, Rossana , Barbati, Giulia , Cipriani, Manlio , Agostoni, Piergiuseppe , Adler, Eric D , Sinagra, Gianfranco

Mayo Clinic

European Journal of Heart Failure | July 1, 2021 | Volume: 23 | Issue: 12 | Pages: 2045-2054

10.1002/ejhf.2288 | PMID 34196079 Get It

Aims The outcomes of patients presenting with acute myocarditis and life‐threatening ventricular arrhythmias (LT‐VA) are unclear. The aim of this study was to assess the incidence and predictors of recurrent major arrhythmic events (MAEs) after hospital discharge in this patient population. Methods and results We retrospectively analysed 156 patients (median age 44 years; 77% male) discharged with a diagnosis of acute myocarditis and LT‐VA from 16 hospitals worldwide. Diagnosis of myocarditis was based on histology or the combination of increased markers of cardiac injury and cardiac magnetic resonance (CMR) Lake Louise criteria. MAEs were defined as the relapse, after discharge, of sudden cardiac death or successfully defibrillated ventricular fibrillation, or sustained ventricular tachycardia (sVT) requiring implantable cardioverter‐defibrillator therapy or synchronized external cardioversion. Median follow‐up was 23 months [first to third quartile (Q1–Q3) 7–60]. Fifty‐eight (37.2%) patients experienced MAEs after discharge, at a median of 8 months (Q1–Q3 2.5–24.0 months; 60.3% of MAEs within the first year). At multivariable Cox analysis, variables independently associated with MAEs were presentation with sVT [hazard ratio (HR) 2.90, 95% confidence interval (CI) 1.38–6.11]; late gadolinium enhancement involving ≥2 myocardial segments (HR 4.51, 95% CI 2.39–8.53), and absence of positive short‐tau inversion recovery (STIR) (HR 2.59, 95% CI 1.40–4.79) at first CMR. Conclusions Among patients discharged with a diagnosis of myocarditis and LT‐VA, 37.2% had recurrences of MAEs during follow‐up. Initial CMR pattern and sVT at presentation stratify the risk of arrhythmia recurrence.
Characteristics of Early-Onset vs Late-Onset Colorectal Cancer
Collaborative, REACCT, Zaborowski, Alexandra , Abdile, Ahmed, Adamina, Michel , Aigner, Felix , d’Allens, Laura, Allmer, Caterina, Álvarez, Andrea, Anula, Rocío, Atallah, S. , Bach, Simon P. , Barussaud, Marie, Baušys, Augustinas , Bebington, Brendan , Beggs, Andrew D. , Bellolio, Felipe, Bennett, Melissa-Rose , Berdinskikh, Anton, Bevan, Vicki, Bislenghi, Gabriele , Bludau, Marc , Boutall, Adam , Brouwer, Nelleke P.M. , Bruns, Christiane J. , Burger, Jacobus W. A. , Бурлов, Никита , Campanelli, Michela , Capdepont, Maylis, Carvello, Michele , Chew, Hwee-Hoon, Christoforidis, Dimitri, Clark, David A. , Climent, Marta, Cologne, Kyle G. , Contreras, Tomás, Croner, Roland S. , Daniels, I. R. , Delrio, Paolo , Deutsch, Michael , D’Hoore, André , Drozdov, E. S. , Duek, Daniel, Dunlop, Malcolm G. , Edmundson, Aleksandra , Efetov, Sergey , El‐Hussuna, Alaa , Elliot, Brodie, Espín, Eloy , Faes, Seraina , Faiz, Omar , Frasson, Matteo , Figueiredo, Nuno , Forgan, Tim , Frizelle, Frank , Gadaev, Shamil, Gellona, José, Glyn, Tamara , Gong, Jianping, Barisic, Goran, Greenwood, Emma, Guren, Marianne G. , Guillon, Stephanie, Gutlic, Ida , Hanly, Ann, Hasegawa, Hirotoshi , Iversen, Lene Hjerrild , Hill, James , Hoch, Jiří, Hoffmeister, Michael , Hompes, Roel , Hurtado‐Pardo, Luis , Iaquinandi, Fabiano , Imbrasaitė, Ugnė , Jafari, Mehrenah Dorna, Kanemitsu, Yukihide , Karimuddin, Ahmer , Keller, Deborah S. , Kelly, Justin, Kennelly, Rory , Khrykov, Gleb , Kocián, Petr , Koh, Cherry , Kok, N. F. M., Knight, Katrina , Knol, Joep, Kontovounisios, Christos , Kørner, Hartwig , Kronberger, Irmgard, Kroon, Hidde M. , Kural, Said , Lakkis, Zaher , Lankov, Timur , Larson, Dave, Lázár, György , Lee, Kai-Yin , Lepistö, Anna , Loi, Lynette , Lynch, Craig, Maillou‐Martinaud, Helene, Maroli, Annalisa , Martling, Anna , Matzel, Klaus E. , Mayol, Julio , McDermott, Frank , Meurette, G. , Mitteregger, Martin , Моисеенко, А С, Monson, John R.T. , Moritani, Konosuke , Munini, Martino , Nahas, Caio Sérgio Rizkallah , Negoi, Ionuţ , Novikova, A , Ocares, Misael, Olkina, Alexandra, Oñate‐Ocaña, Luis F. , Otero, Jaime, Özen, Cihan , Pace, Ugo , Julião, Guilherme Pagin São , Panaiotti, Lidiia , Panís, Yves , Papamichael, Demetris , Uriburu, Juan C Patrón , Pera, Miguél , Perez, Rodrigo Oliva , Pfeffer, F. , Phang, P. Terry , Poškus, Tomas , Pringle, Heather , Proud, David , Raguz, Ivana , Rama, N. , Rasheed, Shahnawaz, Raval, Manoj J. , Reißfelder, Christoph , Meneses, Juan Carlos Reyes , Ris, Frédéric , Riss, Stefan , Rodríguez‐Zentner, Homero , Saklani, Avanish , Salido, Andrea Jiménez, Sammour, Tarik , Saraste, Deborah , Schneider, Martin , Seishima, Ryo , Sekulic, Aleksander , Seppälä, Toni T. , Sheahan, Kieran , Shine, Rebecca , Shlomina, Alexandra , Sica, Guiseppe S., Singnomklao, T, Siragusa, Leandro , Spinelli, Antonino , Staiger, Roxane D. , Stamos, Michael J. , Sunderland, Michael, Tan, Ker‐Kan , Tanis, Pieter J. , Tekkis, Paris, Teklay, Biniam, Tengku, Sabrina , Jiménez‐Toscano, Marta , Turina, Matthias , Ulrich, Alexis , Vailati, Bruna Borba , Harten, Meike van, Warrier, Satish K. , Wexner, Steve, Wilt, Hans De, Xynos, Evangelos , You, Nancy, Zakharenko, Alexander, Zeballos, Justino, Winter, D. C. , Wexner, Steven D. , Hoffmeister, Michael , Seppälä, Toni T , Spinelli, Antonino , Wexner, Steven D , Ris, Frederic , Collaborative, REACCT, Andric, Mihailo , Bala, Miklosh , Biondo, Sebastiano , Brown, Carl James , Buchanan, Daniel D. , Buchwald, Pamela , Dapri, Giovanni , Davies, Justin , Denost, Quentin , Dias, André Roncon , Dziki, Adam Janusz , Emile, Sameh Hany , Evans, Martyn D. , Fleming, Fergal J. , Foppa, Caterina , Fowler, G , Gong, Jianping, Greenwood, Emma, Hahnloser, Dieter , Hampel, Heather , Hill, Andrew Graham , Islam, Rumana, Jafari, Mehrenah D, Карачун, А. М. , Krivokapić, Zoran , Kryžauskas, Marius , Kusters, Miranda , Lee, Suk-Hwan , Lefèvre, Jérémie H. , Lieu, Christopher H. , Martin, Sean, Millán, Mónica , Morărașu, Ștefan , Möslein, Gabriela , Nahas, Sérgio Carlos , Okabayashi, Koji , Олькина, Александра Юрьевна , Park, Jason , Patel, Swati , Petrov, Alexei, Rega, Daniela , Roxburgh, Campbell S.D. , Smart, Neil James , Solis, Alejandro, Steele, Scott R. , Владимирович, Царьков Петр , Verhoef, Cornelis , Weinberg, Benjamin A. , Wells, Cameron I. , Wolthuis, Albert M.

Mayo Clinic

JAMA Surgery | June 30, 2021 | Volume: 156 | Issue: 9 | Pages: 865

10.1001/jamasurg.2021.2380 | PMID 34190968 Get It

Impact of geography on prognostic outcomes of 21,509 patients with metastatic colorectal cancer enrolled in clinical trials: an ARCAD database analysis
Yin, Jun , Dawood, Shaheenah , Cohen, Romain , Meyers, Jeff, Zalcberg, John , Seymour, Michel , Maughan, Tim , Schmoll, Hans‐Joachim , Goldberg, Richard M. , Hoff, Paulo M. , Hecht, J. Randolph , Hurwitz, Herbert I. , Punt, Cornelis J.A. , Rubio, Eduard Diaz, Koopman, Miriam , Cremolini, Chiara , Heinemann, Volker , Tournigard, Christophe, Bokemeyer, Carsten , Fuchs, Charles S. , Souglakos, John , Doulliard, Jean-Yves, Kabbinavar, Fairooz F. , Chibaudel, Benoist , Gramont, Aimery de , Shi, Qian , Adams, Richard , Adams, Richard , Shi, Qian , Maughan, Timothy S , Seymour, Matthew T , Zalcberg, John , Schmoll, Hans-Joachim , Cremolini, Chiara , Chibaudel, Benoist , Cohen, Romain , Yoshino, Takayuki , Saltz, Leonard B. , Cutsem, Eric Van , Venook, Alan P. , Rubio, Eduard Diaz, Tebbutt, Niall C. , Grothey, Axel

Mayo Clinic

Therapeutic Advances in Medical Oncology | June 30, 2021 | Volume: 13 | Issue: No issue available | Pages: No page available

10.1177/17588359211020547 | PMID 34262614 Get It

Background: Benchmarking international cancer survival differences is necessary to evaluate and improve healthcare systems. Our aim was to assess the potential regional differences in outcomes among patients with metastatic colorectal cancer (mCRC) participating in international randomized clinical trials (RCTs). Design: Countries were grouped into 11 regions according to the World Health Organization and the EUROCARE model. Meta-analyses based on individual patient data were used to synthesize data across studies and regions and to conduct comparisons for outcomes in a two-stage random-effects model after adjusting for age, sex, performance status, and time period. We used mCRC patients enrolled in the first-line RCTs from the ARCAD database, which provided enrolling country information. There were 21,509 patients in 27 RCTs included across the 11 regions. Results: Main outcomes were overall survival (OS) and progression-free survival (PFS). Compared with other regions, patients from the United Kingdom (UK) and Ireland were proportionaly over-represented, older, with higher performance status, more frequently male, and more commonly not treated with biological therapies. Cohorts from central Europe and the United States (USA) had significantly longer OS compared with those from UK and Ireland ( p = 0.0034 and p < 0.001, respectively), with median difference of 3–4 months. The survival deficits in the UK and Ireland cohorts were, at most, 15% at 1 year. No evidence of a regional disparity was observed for PFS. Among those treated without biological therapies, patients from the UK and Ireland had shorter OS than central Europe patients ( p < 0.001). Conclusions: Significant international disparities in the OS of cohorts of mCRC patients enrolled in RCTs were found. Survival of mCRC patients included in RCTs was consistently lower in the UK and Ireland regions than in central Europe, southern Europe, and the USA, potentially attributed to greater overall population representation, delayed diagnosis, and reduced availability of therapies.